New 2025 ATA Thyroid Cancer Guidelines Shift More Patients Into Higher Risk Categories
A real-world validation of updated thyroid cancer risk guidelines finds a major reclassification shift — with a newly defined middle-risk group needing closer study.
Summary
The American Thyroid Association updated its risk classification system for papillary thyroid cancer in 2025. Researchers in Milan tested these new guidelines on 670 real patients to see how well they work. Compared to the 2015 system, the new guidelines moved 22% fewer patients into the low-risk category, while intermediate- and high-risk groups grew substantially. A brand-new category called 'low-intermediate-risk' emerged, sitting between the old low- and intermediate-risk groups in terms of actual disease outcomes. This new middle tier had meaningfully different recurrence rates than either neighboring category, suggesting it captures a genuinely distinct patient population. The findings highlight that the 2025 guidelines change how patients are managed and that this new risk group needs dedicated prospective research to determine the best treatment approach.
Detailed Summary
Accurate risk stratification in papillary thyroid cancer (PTC) directly shapes treatment intensity — from the extent of surgery to radioiodine use and follow-up frequency. The American Thyroid Association released updated guidelines in 2025, revising the risk classification system it last overhauled in 2015. Before these new guidelines can confidently guide clinical practice, they need real-world validation.
Researchers at a tertiary care center in Milan conducted a retrospective study of 670 PTC patients with complete histopathological data and known disease outcomes. They reclassified each patient under both the 2015 and 2025 ATA systems and compared how the two systems predicted structural disease persistence — meaning detectable cancer remaining after initial treatment.
The reclassification produced a notable shift toward higher-risk designations. The proportion of patients in the low-risk category fell by 22.2%, while intermediate-risk and high-risk groups grew by 41.7% and 14.9%, respectively. The 2025 low-risk and high-risk classes performed comparably to their 2015 counterparts in predicting outcomes. However, the new 'low-intermediate-risk' class — a category that did not exist in 2015 — stood out as genuinely distinct, with structural disease persistence rates statistically higher than the old low-risk group but lower than the old intermediate-risk group.
This finding is clinically significant because it suggests the 2025 system is not simply relabeling existing groups but is identifying a real intermediate population that may require a tailored management approach — neither the watchful waiting appropriate for low-risk patients nor the aggressive treatment used for intermediate-risk ones.
The main caveat is that this is a retrospective, single-center study, and the summary is based on the abstract only. Prospective multicenter studies are needed to determine optimal management strategies for the newly defined low-intermediate-risk class before widespread clinical adoption.
Key Findings
- The 2025 ATA system moved 22% fewer PTC patients into the low-risk category compared to 2015 guidelines.
- Intermediate-risk and high-risk PTC classifications increased by 41.7% and 14.9%, respectively.
- A new 'low-intermediate-risk' class showed disease persistence rates statistically distinct from both neighboring categories.
- The 2025 low-risk and high-risk classes predicted outcomes comparably to their 2015 equivalents.
- Prospective studies are urgently needed to define optimal management for the new low-intermediate-risk group.
Methodology
This was a retrospective observational study conducted at a tertiary care center in Milan, Italy, including 670 PTC patients with complete histopathological data and documented final disease outcomes. Patients were reclassified under both the 2015 and 2025 ATA risk stratification systems, and structural disease persistence rates were compared across corresponding risk classes using statistical testing.
Study Limitations
This is a retrospective, single-center study, which limits generalizability to broader patient populations and introduces potential selection bias inherent to tertiary care settings. The summary is based on the abstract only, as the full text was not available, so methodological details and subgroup analyses cannot be fully assessed. The study does not provide prospective outcome data or randomized treatment comparisons for the newly defined risk classes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.